← All organizations
Highest phase reached
Phase 3
First clinical trial
Apr 1, 2001Last known activity
Feb 18, 2026
Timeline
2000s
- Jun 1, 2000
Immune Tolerance Network— Founded
Drugs by trial phase (72 distinct, 55 trials)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (60 own, 0 via acquisition)
Indications
Studied for
- Arthritis
- Arthritis, Psoriatic
- Asthma
- Autoimmune Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Eczema
- Egg Hypersensitivity
- Food Hypersensitivity
- Glomerulonephritis, Membranous
- Granulomatosis with Polyangiitis
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- Hypersensitivity
- Hypersensitivity, Immediate
- Kidney Diseases
- Kidney Failure, Chronic
- Liver Diseases
- Liver Failure
- Lupus Erythematosus, Systemic
- Lupus Nephritis
- Microscopic Polyangiitis
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Nephritis
- Peanut Hypersensitivity
- Psoriasis
- Renal Insufficiency
- Rhinitis
- Rhinitis, Allergic
- Rhinitis, Allergic, Seasonal
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Sclerosis
- Systemic Vasculitis
- Vasculitis
Recent trials (50)
- NCT07015996CollaboratorPhase 2Feb 18, 2026
- NCT05671757CollaboratorPhase 1/Phase 2May 26, 2023
- NCT05306353CollaboratorPhase 2Dec 1, 2022
- NCT04827979CollaboratorPhase 1/Phase 2Nov 30, 2021
- NCT05017545CollaboratorPhase 1/Phase 2Nov 30, 2021
- NCT05027815CollaboratorPhase 1Oct 11, 2021
- NCT04761822CollaboratorPhase 2Apr 7, 2021
- NCT04502966CollaboratorPhase 2Nov 9, 2020
- NCT03949855CollaboratorPhase 2Sep 30, 2019
- NCT03654040CollaboratorPhase 1/Phase 2Oct 1, 2018
- NCT03577431CollaboratorPhase 1/Phase 2Oct 1, 2018
- NCT03504241CollaboratorPhase 1Jul 27, 2018
- NCT03222492CollaboratorPhase 1/Phase 2Sep 20, 2017
- NCT02163122CollaboratorEarly Phase 1Jan 1, 2015
- NCT02293837CollaboratorPhase 2Jan 1, 2015
Details
- Founded
- Seattle, WA, US Jun 1, 2000
- Last known activity
- Feb 18, 2026